ChEMBL ligand: CHEMBL177880 (Pamoic Acid)
DNA polymerase beta in Human [ChEMBL: CHEMBL2392] [GtoPdb: 3231] [UniProtKB: P06746] There should be some charts here, you may need to enable JavaScript!
GPR35/G-protein coupled receptor 35 in Human [ChEMBL: CHEMBL1293267] [GtoPdb: 102] [UniProtKB: Q9HC97] GPR35 in Rat [GtoPdb: 102] [UniProtKB: Q33BM1] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
DNA polymerase beta in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2392] [GtoPdb: 3231] [UniProtKB: P06746]
ChEMBL	Inhibition of DNA polymerase beta (unknown origin)	B	5.05	pIC50	9000	nM	IC50	J Med Chem (2013) 56: 5182-5197 [PMID:23713606]
GPR35/G-protein coupled receptor 35 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1293267] [GtoPdb: 102] [UniProtKB: Q9HC97]
ChEMBL	Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide	B	7.64	pKi	23	nM	Ki	ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394]
ChEMBL	Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 20 nM of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide	B	7.83	pKi	14.9	nM	Ki	ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394]
ChEMBL	Displacement of [3H]PSB-13253 from human recombinant GPR35 exprssed in CHO cells by liquid scintillation counting analysis	B	7.94	pKi	11.5	nM	Ki	J Med Chem (2013) 56: 7084-7099 [PMID:23888932]
ChEMBL	Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 50 nM of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide	B	7.99	pKi	10.3	nM	Ki	ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394]
ChEMBL	Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 100 nM of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide	B	8.02	pKi	9.6	nM	Ki	ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394]
ChEMBL	Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 40 nM of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide	B	8.05	pKi	8.9	nM	Ki	ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394]
ChEMBL	Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay	B	5.92	pEC50	1200	nM	EC50	J Med Chem (2013) 56: 7084-7099 [PMID:23888932]
ChEMBL	Agonist activity at GPR-35 (unknown origin) by beta-arrestin assay	B	5.92	pEC50	1200	nM	EC50	ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394]
ChEMBL	GPCR PRESTO-Tango dose-response in agonist mode with target: GPR35	F	6.23	pEC50	590.65	nM	EC50	EUbOPEN Chemogenomics Library - GPCR Dose-Respose
ChEMBL	Agonist activity at human GPR35 receptor expressed in HEK293T cells co-expressing beta-arrestin2 assessed as induction of beta-arrestin2 recruitment by BRET assay	F	6.3	pEC50	500	nM	EC50	J Med Chem (2021) 64: 2634-2647 [PMID:33630609]
ChEMBL	Agonist activity at human GPR35 expressed in CHO-K1 cells after 90 mins by beta-arrestin 2 recruitment assay	B	6.3	pEC50	500	nM	EC50	J Med Chem (2017) 60: 362-372 [PMID:27976894]
GtoPdb	-	-	7.29	pEC50	-	-	-	Biochem J (2010) 432: 451-9 [PMID:20919992]
ChEMBL	Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay	B	7.3	pEC50	50	nM	EC50	J Med Chem (2013) 56: 5182-5197 [PMID:23713606]
ChEMBL	Agonist activity at human GPR35 by beta-arrestin recruitment assay	F	7.52	pEC50	30	nM	EC50	Bioorg Med Chem (2023) 96: 117511-117511 [PMID:37976806]
ChEMBL	Agonist activity at GPR-35 (unknown origin) expressed in HT-29 cells by DMR assay	B	8.52	pEC50	3	nM	EC50	ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394]
ChEMBL	Agonist activity at human GPR35 by DMR assay	B	8.68	pEC50	2.1	nM	EC50	J Med Chem (2013) 56: 7084-7099 [PMID:23888932]
ChEMBL	Agonist activity at human GPR35 receptor expressed in HT-29 cells assessed as dynamic mass redistribution response measured for 60 mins by DMR assay	F	8.7	pEC50	2	nM	EC50	J Med Chem (2021) 64: 2634-2647 [PMID:33630609]
ChEMBL	Agonist activity at human GPR35 expressed in CHO-K1 cells by DMR assay	B	8.7	pEC50	2	nM	EC50	J Med Chem (2017) 60: 362-372 [PMID:27976894]
GPR35 in Rat [GtoPdb: 102] [UniProtKB: Q33BM1]
GtoPdb	-	-	5	pEC50	-	-	-	Biochem J (2010) 432: 451-9 [PMID:20919992]

ChEMBL data shown on this page come from version 35:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]